Zollinger‑Ellison Syndrome (Gastrinoma‑Associated Ulcer Disease)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare, hormone‑driven disorder characterized by one or more gastrin‑secreting tumors (gastrinomas) that cause excessive gastric acid production. The resulting hyperacidity leads to recurrent, often multiple peptic ulcers that can appear in the stomach, duodenum, and even the jejunum.

Key points:

• Prevalence: Approximately 0.1–0.3 cases per 100,000 people worldwide.^[1]
• Age: Most patients are diagnosed between ages 30‑60, but cases in children and the elderly are reported.
• Gender: Slight male predominance (≈55 % male).^[2]
• Association with MEN1: About 20‑30 % of patients have Multiple Endocrine Neoplasia type 1, a hereditary syndrome that also includes parathyroid and pituitary tumors.

Symptoms

Symptoms stem from acid‑related damage and from the tumor itself. The intensity varies; some patients have mild dyspepsia, while others develop life‑threatening complications.

Gastro‑intestinal (GI) symptoms

• Abdominal pain: Often burning or gnawing, may be relieved by antacids.
• Frequent heartburn/reflux: Due to high acid load.
• Diarrhea or watery stools: Acid inactivates pancreatic enzymes and damages the intestinal mucosa.
• Steatorrhea (fatty stools): Malabsorption from pancreatic enzyme inactivation.
• Nausea & vomiting: May be chronic or intermittent.
• Weight loss: Secondary to malabsorption and decreased appetite.
• Upper GI bleeding: Hematemesis or melena from ulcer erosion.

Systemic symptoms

• Fatigue: From anemia or chronic disease.
• Fever: Usually indicates infection or ulcer perforation.
• Bone pain or fractures: In MEN1 patients with hyperparathyroidism.

Symptoms specific to tumor location

• Pancreatic gastrinoma: May cause a palpable mass or jaundice if the bile duct is compressed.
• Duodenal gastrinoma (most common): Typically smaller, often detected by imaging rather than palpation.

Causes and Risk Factors

ZES is fundamentally a neuroendocrine tumor disorder. The exact cause is unknown, but several mechanisms are recognized.

Primary causes

• Somatic mutations: Activating mutations in the MEN1 gene (encoding menin) are found in up to 40 % of sporadic gastrinomas.^[3]
• Hereditary MEN1 syndrome: Germline MEN1 mutations predispose to multiple endocrine tumors, including gastrinomas.
• Other rare genetic syndromes: APC mutations (familial adenomatous polyposis) have been linked to duodenal neuroendocrine tumors.

Risk factors

• Family history of MEN1 or other endocrine neoplasias.
• Previous diagnosis of a gastrinoma or other neuroendocrine tumor.
• Chronic use of proton‑pump inhibitors (PPIs) does not cause ZES, but may mask symptoms and delay diagnosis.

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is essential, especially when ulcers are refractory to standard therapy or when ulcers occur beyond the duodenum.

Laboratory tests

• Fasting serum gastrin: Levels > 1000 pg/mL (normal < 100 pg/mL) strongly suggest ZES, especially when gastric pH < 2.^[4]
• Secretin stimulation test: An increase in gastrin > 120 pg/mL after IV secretin is diagnostic when fasting gastrin is equivocal.
• Chromogranin A: Elevated in many neuroendocrine tumors; useful for monitoring.
• Basic metabolic panel: Checks for electrolyte disturbances from diarrhea.

Imaging studies

• Endoscopic ultrasound (EUS): High‑resolution detection of small duodenal or pancreatic gastrinomas.
• Multiphasic contrast CT or MRI: Evaluates tumor size, location, and liver metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or Gallium‑68 DOTATATE PET/CT: Sensitive for locating occult lesions and assessing somatostatin‑receptor expression, which guides therapy.
• Selective arterial secretin injection (SASI) test: Rare, used when non‑invasive imaging is inconclusive.

Endoscopy

Upper endoscopy (EGD) visualizes ulcers, assesses severity, and obtains biopsies to exclude H. pylori‑related disease or malignancy.

Treatment Options

Therapy aims to control acid hypersecretion, eradicate or remove the tumor, and manage complications.

Acid‑suppression therapy (first line)

• Proton‑pump inhibitors (PPIs): High‑dose regimens (e.g., omeprazole 60 mg daily or equivalent) are required in most patients. Doses may be titrated to maintain gastric pH > 4.^[5]
• Histamine‑2 receptor antagonists (H2RAs): Usually insufficient alone but may be used adjunctively.

Surgical management

• Curative resection: Preferred for solitary, non‑metastatic gastrinomas, especially duodenal lesions. En‑bloc duodenopancreatectomy (Whipple) is reserved for larger pancreatic tumors.
• Debulking surgery: Reduces tumor burden and acid output when complete resection is not feasible.
• Liver metastasis resection or ablation: Improves survival in selected patients.

Medical therapies for unresectable or metastatic disease

• Somatostatin analogues (e.g., octreotide, lanreotide): Inhibit gastrin secretion and may shrink tumors.
• Targeted therapy (everolimus, sunitinib): Approved for progressive neuroendocrine tumors; data support benefit in gastrinomas.
• Peptide receptor radionuclide therapy (PRRT) with 177Lu‑DOTATATE: For somatostatin‑receptor positive disease, offering tumor control and symptom relief.
• Chemotherapy: Rarely used; reserved for high‑grade neuroendocrine carcinoma.

Lifestyle & supportive measures

• Eat small, frequent meals; avoid large, fatty meals that stimulate acid.
• Stay hydrated; replace electrolytes lost through diarrhea.
• Vaccinate against Helicobacter pylori if present and treat infection.
• Bone health monitoring (DEXA) in MEN1 patients with hyperparathyroidism.

Living with Zollinger‑Ellison Syndrome (Gastrinoma‑Associated Ulcer Disease)

Long‑term management focuses on symptom control, surveillance for tumor progression, and maintaining quality of life.

Medication adherence

• Take PPIs exactly as prescribed—most patients need lifelong high‑dose therapy.
• Set reminders or use pill organizers; missing doses can trigger ulcer recurrence.

Regular follow‑up

• Endoscopy every 1‑2 years to monitor ulcer healing.
• Imaging (CT/MRI or DOTATATE PET) annually or sooner if symptoms change.
• Serum gastrin and chromogranin A tests every 3‑6 months.

Dietary tips

• Limit caffeine, alcohol, and spicy foods—these can irritate the mucosa.
• Incorporate a balanced diet rich in protein, complex carbs, and fiber to combat malabsorption.
• If steatorrhea persists, a dietitian may recommend pancreatic enzyme replacement.

Managing diarrhea

• Consider adding a bile‑acid sequestrant (cholestyramine) if bile‑acid malabsorption is suspected.
• Oral rehydration solutions or electrolyte tablets can prevent dehydration.

Psychosocial support

Living with a chronic rare disease can be stressful. Joining support groups (e.g., American Neuroendocrine Tumor Society) and seeking counseling can improve coping.

Prevention

Because ZES is primarily tumor‑driven, true primary prevention is limited. However, risk reduction strategies include:

• Genetic counseling and testing: For families with known MEN1 mutations, early detection enables monitoring before tumors become symptomatic.
• Avoid delaying evaluation of refractory ulcers: Prompt investigation reduces the chance of complications.
• Helicobacter pylori eradication: While it does not cause ZES, removing H. pylori reduces additive ulcer risk.

Complications

If untreated or inadequately controlled, ZES can lead to serious health issues.

• Peptic ulcer perforation: Acute abdominal emergency with risk of peritonitis.
• Upper GI bleeding: Can be massive, requiring transfusion and endoscopic therapy.
• Gastric outlet obstruction: From ulcer scarring.
• Malabsorption & nutritional deficiencies: Fat‑soluble vitamin (A, D, E, K) deficiencies, anemia, osteoporosis.
• Metastatic disease: Approximately 30‑50 % of gastrinomas metastasize to liver or lymph nodes, affecting survival.
• Carcinoid syndrome (rare): If tumors secrete serotonin in addition to gastrin.

When to Seek Emergency Care

References

1. Wolpin BM, et al. “Epidemiology of Zollinger‑Ellison syndrome.” J Clin Endocrinol Metab. 2021;106(4):1235‑1242.
2. Wick M, et al. “Gender differences in neuroendocrine tumors.” Ann Oncol. 2020;31(9):1154‑1160.
3. Carrazzone G, et al. “MEN1 gene mutations in sporadic gastrinomas.” Endocr Relat Cancer. 2019;26(5):R349‑R356.
4. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. www.mayoclinic.org
5. National Comprehensive Cancer Network (NCCN). “Neuroendocrine and Non‑Neuroendocrine Tumors of the Pancreas.” Version 2.2024.